Cathie Wood's ARK shifts focus, buys KDK stock and sells KTOS

Cathie Wood's ARK ETFs executed notable portfolio adjustments on September 26, 2025, significantly divesting from Kratos Defense and Security Solutions (KTOS) with a $5.97 million sale and continuing to reduce its position in Roblox (RBLX). Concurrently, ARK increased its exposure to emerging sectors, acquiring 784,610 shares of Ares Acquisition Corporation II (KDK) and 137,696 shares of Intellia Therapeutics (NTLA) valued at $2.29 million, indicating a strategic shift towards SPACs and biotechnology while rebalancing existing holdings.

Analysis

On September 26, 2025, ARK Invest executed a notable portfolio rebalancing, underscored by its largest dollar-value trade of the day: a significant divestment from Kratos Defense and Security Solutions (KTOS). The sale of 70,874 shares, valued at approximately $5.97 million, coupled with a continued reduction in its Roblox (RBLX) holdings through a $3.68 million sale, indicates a strategic capital reallocation away from these positions. Concurrently, ARK fortified its conviction in the biotechnology sector by acquiring 137,696 shares of Intellia Therapeutics (NTLA) for $2.29 million, distributing the purchase across its ARKK and ARKG ETFs. The fund also demonstrated growing interest in special purpose acquisition companies, purchasing 784,610 shares of Ares Acquisition Corporation II, building on a pattern of recent acquisitions in the SPAC. While the article's headline references a buyout report for Electronic Arts (EA), the body of the text provides no supporting details, focusing exclusively on ARK's trading activity, which points to a clear tactical rotation from defense and gaming into biotech and specific SPAC opportunities.

Key Decisions for Investors

• Investors tracking institutional flows should note the significant selling pressure on Kratos Defense (KTOS) and Roblox (RBLX) from a prominent innovation-focused fund, which may signal a bearish shift in ARK's thesis for these companies.
• The consistent accumulation of Intellia Therapeutics (NTLA) and Ares Acquisition Corporation II reinforces ARK's bullish conviction, flagging these names as key areas of focus within the biotech and SPAC sectors for growth-oriented investors.
• It is critical to disregard the headline regarding a potential Electronic Arts (EA) buyout, as the article provides no substantiating details, and investment decisions should be based on the documented trading activity detailed in the text.
• The contrasting movements—selling KTOS and RBLX while buying NTLA and the Ares SPAC—suggest investors should evaluate their own portfolio's alignment with this rotation from established tech/defense into emerging biotech and speculative vehicles.